NextCure (NXTC) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NextCure (NXTC) has outperformed Rein Therapeutics (RNTX) over the past year, losing 38.6% versus a loss of 77.2%. Over five years, NXTC leads with a -91.1% price change compared with -97.5% for RNTX. NextCure is the larger company by market cap ($29.5 million vs $29.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NXTC | RNTX |
|---|---|---|
| Share price | $6.45 | $0.3369 |
| Market cap | $29.53M | $29.06M |
| 1-day change | -4.87% | -8.38% |
| YTD return | -54.55% | -70.96% |
| 1-year return | -38.63% | -77.24% |
| 5-year return | -91.07% | -97.47% |
| EPS (TTM) | $-6.78 | $-1.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-55.84M | $-49.87M |
| 52-week high | $15.74 | $2.10 |
| 52-week low | $1.55 | $0.284 |
| Distance from 52-week high | -59.02% | -83.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +210.08% | +1680.94% |
| Average volume | 79.46K | 586.68K |
| Shares outstanding | 4.58M | 86.27M |
| Employees | 40 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed RNTX by 38.6 percentage points over the past year.
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NXTC vs RNTX FAQ
Which is bigger, NextCure or Rein Therapeutics?
NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $29.06M for Rein Therapeutics (RNTX).
Which stock has performed better over the past year, NXTC or RNTX?
NXTC returned -38.63% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are NextCure and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.